{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:14:46Z","timestamp":1760148886406,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["BA5158\/4"],"award-info":[{"award-number":["BA5158\/4"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Herzstiftung (TSG-Study)","award":["BA5158\/4"],"award-info":[{"award-number":["BA5158\/4"]}]},{"name":"Ministry of Science, Research and Art of Baden-W\u00fcrttemberg, Germany (the CORE Study)","award":["BA5158\/4"],"award-info":[{"award-number":["BA5158\/4"]}]},{"name":"German Red Cross Blood Service Baden-W\u00fcrttemberg-Hessen","award":["BA5158\/4"],"award-info":[{"award-number":["BA5158\/4"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>COVID-19 convalescent plasma (CCP) with high neutralizing antibodies has been suggested in preventing disease progression in COVID-19. In this study, we investigated the relationship between clinical donor characteristics and neutralizing anti-SARS-CoV-2 antibodies in CCP donors. COVID-19 convalescent plasma donors were included into the study. Clinical parameters were recorded and anti-SARS-CoV-2 antibody levels (Spike Trimer, Receptor Binding Domain (RBD), S1, S2 and nucleocapsid protein) as well as ACE2 binding inhibition were measured. An ACE2 binding inhibition &lt; 20% was defined as an inadequate neutralization capacity. Univariate and multivariable logistic regression analysis was used to detect the predictors of inadequate neutralization capacity. Ninety-one CCP donors (56 female; 61%) were analyzed. A robust correlation between all SARS-CoV-2 IgG antibodies and ACE2 binding inhibition, as well as a positive correlation between donor age, body mass index, and a negative correlation between time since symptom onset and antibody levels were found. We identified time since symptom onset, normal body mass index (BMI), and the absence of high fever as independent predictors of inadequate neutralization capacity. Gender, duration of symptoms, and number of symptoms were not associated with SARS-CoV-2 IgG antibody levels or neutralization. Neutralizing capacity was correlated with SARS-CoV-2 IgG antibodies and associated with time since symptom onset, BMI, and fever. These clinical parameters can be easily incorporated into the preselection of CCP donors.<\/jats:p>","DOI":"10.3390\/v15061357","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:35:30Z","timestamp":1686620130000},"page":"1357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-6230","authenticated-orcid":false,"given":"G\u00fcnalp","family":"Uzun","sequence":"first","affiliation":[{"name":"Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany"},{"name":"Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72072 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-W\u00fcrttemberg-Hessen, 68167 Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Althaus","sequence":"additional","affiliation":[{"name":"Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany"},{"name":"Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72072 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-4257","authenticated-orcid":false,"given":"Matthias","family":"Becker","sequence":"additional","affiliation":[{"name":"NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Marsall","sequence":"additional","affiliation":[{"name":"NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Junker","sequence":"additional","affiliation":[{"name":"NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Nowak-Harnau","sequence":"additional","affiliation":[{"name":"Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Schneiderhan-Marra","sequence":"additional","affiliation":[{"name":"NMI Natural and Medical Sciences Institute at the University of Tuebingen, 72770 Reutlingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Kl\u00fcter","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-W\u00fcrttemberg-Hessen, 68167 Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-W\u00fcrttemberg-Hessen, 89081 Ulm, Germany"},{"name":"Institute for Transfusion Medicine and University Hospital Ulm, University of Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bugert","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-W\u00fcrttemberg-Hessen, 68167 Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-6812","authenticated-orcid":false,"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[{"name":"Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen, 72072 Tuebingen, Germany"},{"name":"Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72072 Tuebingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"ref_1","unstructured":"Board, G.P.M. (2020). A World in Disorder: Global Preparedness Monitoring Board Annual Report 2020."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Focosi, D., Franchini, M., Pirofski, L.-A., Burnouf, T., Fairweather, D., Joyner, M.J., and Casadevall, A. (2021). COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 13.","DOI":"10.3390\/v13081594"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Senefeld, J.W., Johnson, P.W., Kunze, K.L., Bloch, E.M., van Helmond, N., Golafshar, M.A., Klassen, S.A., Klompas, A.M., Sexton, M.A., and Diaz Soto, J.C. (2021). Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003872"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1537-2995.2010.02590.x","article-title":"Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product?","volume":"50","author":"Leider","year":"2010","journal-title":"Transfusion"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_8","unstructured":"US Food and Drug Administration (2023, April 15). Emergency Use Authorization, Available online: https:\/\/www.fda.gov\/media\/141477\/download."},{"key":"ref_9","unstructured":"European Commission (2023, April 15). COVID-19: Commission Supports Blood Services to Increase COVID-19 Convalescent Plasma Collection, Available online: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_50."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"684151","DOI":"10.3389\/fmed.2021.684151","article-title":"Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence","volume":"8","author":"Klassen","year":"2021","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e152264","DOI":"10.1172\/JCI152264","article-title":"Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19","volume":"131","author":"Weiss","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e163657","DOI":"10.1172\/JCI163657","article-title":"One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients","volume":"132","author":"Zickler","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_13","first-page":"96","article-title":"Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: A randomized clinical trial","volume":"4","author":"Denkinger","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent Plasma Antibody Levels and the Risk of Death from COVID-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa2119657","article-title":"Early Outpatient Treatment for COVID-19 with Convalescent Plasma","volume":"386","author":"Sullivan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.7326\/M22-1079","article-title":"Clinical Practice Guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma","volume":"175","author":"Estcourt","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_17","unstructured":"FDA (2023, April 15). Recommendations for Investigational COVID-19 Convalescent Plasma, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-applications-inds-cber-regulated-products\/recommendations-investigational-covid-19-convalescent-plasma."},{"key":"ref_18","unstructured":"EU COVID-19 Convalescent Plasma Platform (2023, April 15). COVID-19 Convalescent Plasma Collection and Transfusion. Available online: https:\/\/www.euccp.dataplatform.tech.ec.europa.eu\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1055\/a-1797-0564","article-title":"Platelets and Sera from Donors of Convalescent Plasma after Mild COVID-19 Show No Procoagulant Phenotype","volume":"42","author":"Uzun","year":"2022","journal-title":"Hamostaseologie"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.thromres.2022.06.014","article-title":"Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors","volume":"216","author":"Rink","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41467-021-20973-3","article-title":"Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity","volume":"12","author":"Becker","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1038\/s41598-022-10987-2","article-title":"COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants","volume":"12","author":"Junker","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000515610","article-title":"Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies","volume":"48","author":"Corman","year":"2021","journal-title":"Transfus. Med. Hemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"628971","DOI":"10.3389\/fimmu.2020.628971","article-title":"Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses","volume":"11","author":"Schlickeiser","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., and Kellam, P. (2020). Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15.","DOI":"10.1101\/2020.08.25.20178806"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"732787","DOI":"10.3389\/fpubh.2021.732787","article-title":"Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection","volume":"9","author":"Schiffner","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e144930","DOI":"10.1172\/JCI144930","article-title":"Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates","volume":"131","author":"Boonyaratanakornkit","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1001\/jamainternmed.2020.4616","article-title":"Evaluating the Association of Clinical Characteristics with Neutralizing Antibody Levels in Patients Who Have Recovered from Mild COVID-19 in Shanghai, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41423-020-00573-9","article-title":"Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods","volume":"18","author":"Stein","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100763","DOI":"10.1016\/j.cegh.2021.100763","article-title":"The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors","volume":"11","author":"Wardhani","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/trf.16208","article-title":"A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations","volume":"61","author":"Franchini","year":"2021","journal-title":"Transfusion"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1106664","DOI":"10.3389\/fimmu.2023.1106664","article-title":"Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1146702","DOI":"10.3389\/fimmu.2023.1146702","article-title":"SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study","volume":"14","author":"Parker","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/joim.13185","article-title":"Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial","volume":"289","author":"Madariaga","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nri3843","article-title":"Fever and the thermal regulation of immunity: The immune system feels the heat","volume":"15","author":"Evans","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.4049\/jimmunol.2101156","article-title":"SARS-CoV-2 Antibody Response Is Associated with Age and Body Mass Index in Convalescent Outpatients","volume":"208","author":"Zhai","year":"2022","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/oby.23208","article-title":"The association between obesity and peak antibody titer response in COVID-19 infection","volume":"29","author":"Soffer","year":"2021","journal-title":"Obesity"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Frasca, D., Reidy, L., Cray, C., Diaz, A., Romero, M., Kahl, K., and Blomberg, B.B. (2021). Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245424"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/oby.21383","article-title":"Obesity decreases B cell responses in young and elderly individuals","volume":"24","author":"Frasca","year":"2016","journal-title":"Obesity"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:53:23Z","timestamp":1760126003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["v15061357"],"URL":"https:\/\/doi.org\/10.3390\/v15061357","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}